FIGHT trial investigates GLP-1 agonist therapy for clinical stability in post-Acute Heart Failure Syndrome

Heart failure (HF) remains a significant global health burden, characterized by high morbidity and mortality. While GLP-1 receptor agonists (GLP-1 RAs) have shown promise in heart failure with preserved ejection fraction (HFpEF), their efficacy and safety in heart failure with reduced ejection fraction (HFrEF) have been less clear, with some studies even raising safety concerns. This disparity highlights a critical gap in understanding the full therapeutic potential of GLP-1 RAs across the HF spectrum, particularly in the vulnerable post-acute heart failure syndrome period where clinical stability is paramount. The need for interventions that can improve outcomes in this high-risk population is substantial.